Systems Immunogenetics of Biodefense and Emerging Pathogens in the Collaborative Cross
生物防御和新兴病原体协同交叉的系统免疫遗传学
基本信息
- 批准号:10265701
- 负责人:
- 金额:$ 9.12万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAntiviral AgentsAutoimmunityAutomobile DrivingBiological ModelsClustered Regularly Interspaced Short Palindromic RepeatsData SetDatabasesDiagnosisDiseaseEnvironmental Risk FactorEthicsGene CombinationsGenesGeneticGenetic VariationHealthHumanHypersensitivityImmuneImmune System DiseasesImmune responseImmunityImmunogeneticsInbreedingIndividualInfectionInflammationInfluenza A virusMapsMediatingModelingMorbidity - disease rateMusNatural ImmunityPathogenesisPathologicPathway interactionsPhenotypePlayPopulationQuantitative GeneticsQuantitative Trait LociRecombinantsReproducibilityResearchResearch DesignRoleSARS coronavirusSamplingShapesSignal PathwaySystemTestingTherapeutic InterventionTimeVariantViral PathogenesisVirusVirus DiseasesWest Nile virusadaptive immunitybiodefensecohortemerging pathogengenome editinggenomic locusmortalitymouse geneticspathogenic viruspreventive interventionprogramsrespiratory virusresponsetherapeutic targettoolvaccine efficacyvaccine safety
项目摘要
Abstract: Emerging viruses, such as SARS-CoV, influenza A virus (IAV), and West Nile virus (WNV) cause
high levels of morbidity and mortality in human populations. Host immune responses can play either protective
or a pathologic role during viral infections. Therefore, understanding of the regulatory networks and signaling
pathways that determine the magnitude and quality of an individual's antiviral immune response has important
implications for human health, since these genes/pathways could be therapeutically targeted to treat virus-
induced disease, or may represent targets for enhancing the safety and efficacy of vaccines against a wide
range of viral pathogens.
Polymorphic host genes and regulatory networks have a major impact on immune response variation in human
populations. However, confounding environmental factors and/or ethical concerns limit the types of studies
that can be conducted in humans. Therefore, genetically tractable model systems that capture the range of
genetic and phenotypic diversity seen in humans, such as the Collaborative Cross (CC) are needed to
mechanistically dissect the genetics of immune variation. Our research team has quantified variation in
baseline, as well as SARS-CoV, IAV, and WNV-induced immune responses in a panel of 110 CC RIX lines
(reproducible F1 crosses between CC recombinant inbred (RI) lines that model heterozygous human
populations). To our knowledge, this represents to most comprehensive analysis of immune response variation
ever conducted in a genetic reference population, and in ongoing QTL mapping studies, we have identified
100+ quantitative trait loci (QTL) associated with variation in virus-induced innate and adaptive immunity,
inflammation and disease. Our program, which includes expertise in viral pathogenesis, innate and adaptive
immunity, and quantitative genetics will use this unprecedented data base to: 1) identify and characterize
polymorphic host genes that drive variation in virus-induced disease, 2) test how interactions between different
polymorphic genes/loci shape the host immune response, 3) test how these genes impact responses to other
viral pathogens, or function during allergy/auto-immunity, and 4) test the impact of these genes in the context
of human infections to identify targets for diagnosis, prevention and therapeutic interventions in humans.
These studies will significantly enhance our understanding of how host genetic variation shapes virus-induced
immunity and/or disease.
翻译后摘要:新兴的病毒,如SARS冠状病毒,甲型流感病毒(IAV),西尼罗河病毒(WNV)的原因
人口发病率和死亡率高。宿主的免疫反应既可以起到保护作用,
或在病毒感染过程中的病理作用。因此,了解监管网络和信号
决定个体抗病毒免疫应答的大小和质量的途径具有重要的
对人类健康的影响,因为这些基因/途径可以在治疗上靶向治疗病毒-
诱导的疾病,或可能代表用于增强疫苗针对广泛的
一系列病毒病原体。
多态性宿主基因和调节网络对人类免疫反应变异产生重大影响
人口。然而,混杂的环境因素和/或伦理问题限制了研究的类型
可以在人类身上进行的实验。因此,遗传上易于处理的模型系统,捕捉的范围,
人类的遗传和表型多样性,如协作杂交(CC),
机械地剖析免疫变异的遗传学。我们的研究团队已经量化了
基线,以及SARS-CoV,IAV和WNV诱导的免疫应答,在一组110个CC RIX系中
(在CC重组近交(RI)系之间的可再现的F1杂交,所述CC重组近交(RI)系模拟杂合人类
人口)。据我们所知,这代表了对免疫应答变化的最全面的分析
在遗传参考群体中进行的,以及正在进行的QTL定位研究中,我们已经确定了
100多个与病毒诱导的先天性和适应性免疫变异相关的数量性状基因座(QTL),
炎症和疾病。我们的计划,其中包括病毒发病机制,先天和适应性的专业知识
免疫学和数量遗传学将使用这一前所未有的数据库:1)识别和表征
多态性宿主基因驱动病毒诱导的疾病的变化,2)测试不同之间的相互作用
多态性基因/基因座塑造宿主免疫应答,3)测试这些基因如何影响对其他免疫应答的反应,
病毒病原体,或在过敏/自身免疫过程中的功能,以及4)测试这些基因在背景下的影响
以确定人类诊断、预防和治疗干预的目标。
这些研究将显著增强我们对宿主遗传变异如何塑造病毒诱导的
免疫和/或疾病。
项目成果
期刊论文数量(85)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Viral metagenomics, protein structure, and reverse genetics: Key strategies for investigating coronaviruses.
病毒宏基因组学、蛋白质结构和反向遗传学:研究冠状病毒的关键策略。
- DOI:10.1016/j.virol.2017.12.009
- 发表时间:2018-04
- 期刊:
- 影响因子:3.7
- 作者:Johnson BA;Graham RL;Menachery VD
- 通讯作者:Menachery VD
MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis.
MERS-COV辅助ORF在感染和发病机理中起关键作用。
- DOI:10.1128/mbio.00665-17
- 发表时间:2017-08-22
- 期刊:
- 影响因子:6.4
- 作者:Menachery VD;Mitchell HD;Cockrell AS;Gralinski LE;Yount BL Jr;Graham RL;McAnarney ET;Douglas MG;Scobey T;Beall A;Dinnon K 3rd;Kocher JF;Hale AE;Stratton KG;Waters KM;Baric RS
- 通讯作者:Baric RS
Genetic diversity in the collaborative cross model recapitulates human West Nile virus disease outcomes.
- DOI:10.1128/mbio.00493-15
- 发表时间:2015-05-05
- 期刊:
- 影响因子:6.4
- 作者:Graham JB;Thomas S;Swarts J;McMillan AA;Ferris MT;Suthar MS;Treuting PM;Ireton R;Gale M Jr;Lund JM
- 通讯作者:Lund JM
Of mice and men: the host response to influenza virus infection.
- DOI:10.1007/s00335-018-9750-y
- 发表时间:2018-08
- 期刊:
- 影响因子:0
- 作者:Kollmus H;Pilzner C;Leist SR;Heise M;Geffers R;Schughart K
- 通讯作者:Schughart K
A Reverse Genetics Platform That Spans the Zika Virus Family Tree.
- DOI:10.1128/mbio.02014-16
- 发表时间:2017-03-07
- 期刊:
- 影响因子:6.4
- 作者:Widman DG;Young E;Yount BL;Plante KS;Gallichotte EN;Carbaugh DL;Peck KM;Plante J;Swanstrom J;Heise MT;Lazear HM;Baric RS
- 通讯作者:Baric RS
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ralph S Baric其他文献
Ralph S Baric的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ralph S Baric', 18)}}的其他基金
Development of direct-acting flavivirus inhibitors
直接作用黄病毒抑制剂的开发
- 批准号:
10513687 - 财政年份:2022
- 资助金额:
$ 9.12万 - 项目类别:
Research Project 1: Coronavirus antiviral lead development and combination testing
研究项目1:冠状病毒抗病毒先导药物开发和组合测试
- 批准号:
10513684 - 财政年份:2022
- 资助金额:
$ 9.12万 - 项目类别:
RAPIDLY EMERGING ANTIVIRAL DRUG DEVELOPMENT INITIATIVE- AViDD CENTER (READDI-AC)
迅速崛起的抗病毒药物开发计划 - AViDD 中心 (READDI-AC)
- 批准号:
10513679 - 财政年份:2022
- 资助金额:
$ 9.12万 - 项目类别:
Development of Antivirals against Filovirus Replication
抗丝状病毒复制的抗病毒药物的开发
- 批准号:
10513686 - 财政年份:2022
- 资助金额:
$ 9.12万 - 项目类别:
Systems Immunogenetics of Emerging Coronavirus Infections in the Collaborative Cross
协作交叉中新出现的冠状病毒感染的系统免疫遗传学
- 批准号:
10180497 - 财政年份:2020
- 资助金额:
$ 9.12万 - 项目类别:
North Carolina Seronet Center for Excellence
北卡罗来纳州 Seronet 卓越中心
- 批准号:
10855051 - 财政年份:2020
- 资助金额:
$ 9.12万 - 项目类别:
Project 1: Serological Correlates of SARS CoV2 Immunity and Disease
项目 1:SARS CoV2 免疫与疾病的血清学相关性
- 批准号:
10688377 - 财政年份:2020
- 资助金额:
$ 9.12万 - 项目类别:
Human antibody-based countermeasures against the Coronavirus SARS-CoV-2
基于人类抗体的冠状病毒 SARS-CoV-2 对策
- 批准号:
10264078 - 财政年份:2020
- 资助金额:
$ 9.12万 - 项目类别:
相似国自然基金
基于激发植物免疫为导向的嘧啶酮类高效抗病毒剂设计合成及作用机制研究
- 批准号:21807037
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
基于kealiinine类海洋生物碱的新型抗病毒剂的设计合成、构效关系及作用机制研究
- 批准号:21772145
- 批准年份:2017
- 资助金额:64.0 万元
- 项目类别:面上项目
植物用抗病毒剂的研究
- 批准号:28900011
- 批准年份:1989
- 资助金额:3.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 9.12万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 9.12万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 9.12万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 9.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 9.12万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 9.12万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 9.12万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 9.12万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 9.12万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 9.12万 - 项目类别: